Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp to Distribute Sera's PreTRM Test, Lead $40M Series C Round

NEW YORK (GenomeWeb) – Sera Prognostics said today it has tapped Laboratory Corporation of America to be the exclusive US distributor of Sera's PreTRM test for preterm birth.

Sera noted that LabCorp's existing non-invasive prenatal testing, women's healthcare, and reproductive genetics businesses make it well positioned to drive commercialization of the test.

"As a market leader in NIPT, women’s health and reproductive genetics, LabCorp brings a significant depth of experience that will help expand the commercialization of PreTRM," Sera Chairman and CEO Gregory Critchfield added in a statement.

The PreTRM test measures the levels of two proteins in blood to predict a pregnant woman's risk of giving preterm birth. Sera launched the test in a limited release last year and plans to make it available nationwide in 2017 through the LabCorp collaboration.

LabCorp will also lead a $40 million Series C funding round for Sera, the proceeds of which the company will use to collect clinical data to support reimbursement and expand commercial availability of PreTRM nationwide.

Financial and other terms of the agreement were not disclosed.